Literature DB >> 16116305

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Richard M Rutstein1, Kelly A Gebo, Patricia M Flynn, John A Fleishman, Victoria L Sharp, George K Siberry, Stephen A Spector.   

Abstract

BACKGROUND: The goal of highly active antiretroviral therapy (HAART) has been to stabilize and reconstitute immune function and suppress viral replication to the greatest degree possible. Suppression of HIV viral replication has been associated with improved long-term and short-term prognosis. Limited data are available on the level of virologic suppression and immune function of pediatric patients followed in clinical settings in the HAART era.
OBJECTIVE: The objective of this study was to assess the level of virologic suppression and immune function in a cohort of children with perinatally acquired HIV infection followed at dedicated HIV specialty care sites. RESEARCH
DESIGN: This study comprised a cohort study of HIV-infected children and adolescents.
SUBJECTS: Study subjects consisted of 263 HIV-positive children (<or=17 years old), on HAART, with at least one outpatient visit and CD4 test recorded in 2001 seen at 4 U.S. HIV primary pediatrics and specialty care sites (2 eastern, 1 southern, and 1 western). MEASURES: Measures consisted of all plasma HIV-1 RNA levels <or=400 during calendar year 2001.
RESULTS: Two hundred sixty-three patients received HIV-related treatment during 2001, with a mean age of 8.5 years. Sixty-eight percent were black, 54% were females, and the majority (85%) was insured by Medicaid. A total of 28.6% had a class C AIDS diagnosis. A total of 23.5% and 34% of patients maintained viral suppression at <50 copies per milliliter (cpm), or <400 cpm, respectively, for the calendar year; 32.5% and 38.8%, respectively, fulfilled the criteria if one "blip" to <5000 cpm was allowed. Forty-eight percent maintained all viral loads <5000 cpm, and 74.9% overall had HIV-1 RNAs <or=15,000 cpm. Eighty-seven percent of patients had CD4% >25; only 4.2% had CD4 <15%. Overall, 12.5% of patients had either CD4% <15 or severely decreased absolute CD4 counts (adjusted for age). A total of 4.6% of patients had HIV-1 RNAs >100,000 cpm and severe immunosuppression. Patients who were less likely to achieve virologic suppression to <400 cpm included those with CD4 count <200 cells/mm(3) (odds ratio [OR], 0.06; 95% confidence interval [CI], 0.007-0.46), those with AIDS (OR, 0.5; 95% CI, 0.28-0.94), and those with moderate (OR, 0.42; 95% CI, 0.22-0.79), or severe immunologic suppression (OR, 0.14; 95% CI, 0.046-0.43) based on CD4%.
CONCLUSION: In this multisite, pediatric cohort, the rate of near-complete virologic suppression (<50 or <400 cpm) was low. However, the majority of patients have near-normal CD4 counts and viral loads <15,000 cpm. Follow up will be critical to assess the implications of ongoing low-level viral replication with near-normal CD4 values.

Entities:  

Mesh:

Year:  2005        PMID: 16116305     DOI: 10.1097/01.mlr.0000175636.34524.b9

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  7 in total

1.  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Authors:  Paul Krogstad; Kunjal Patel; Brad Karalius; Rohan Hazra; Mark J Abzug; James Oleske; George R Seage; Paige L Williams; William Borkowsky; Andrew Wiznia; Jorge Pinto; Russell B Van Dyke
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

2.  Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring?

Authors:  Sarah Finocchario-Kessler; Jacinda K Dariotis; Michael D Sweat; Maria E Trent; Jean M Keller; Quratulain Hafeez; Jean R Anderson
Journal:  AIDS Patient Care STDS       Date:  2010-05       Impact factor: 5.078

Review 3.  The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities.

Authors:  Brian C Zanoni; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2014-03       Impact factor: 5.078

4.  Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children.

Authors:  Ravinder Singh; Aparna Mukherjee; Mohit Singla; Bimal Kumar Das; Sushil Kumar Kabra; Rakesh Lodha
Journal:  Indian J Pediatr       Date:  2017-09-06       Impact factor: 1.967

5.  Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.

Authors:  Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

6.  High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain.

Authors:  Miguel de Mulder; Gonzalo Yebra; Adriana Navas; María Isabel de José; María Dolores Gurbindo; María Isabel González-Tomé; María José Mellado; Jesús Saavedra-Lozano; María Ángeles Muñoz-Fernández; Santiago Jiménez de Ory; José Tomás Ramos; Africa Holguín
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

7.  Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Authors:  Anand Reddi; Sarah C Leeper; Anneke C Grobler; Rosemary Geddes; K Holly France; Gillian L Dorse; Willem J Vlok; Mbali Mntambo; Monty Thomas; Kristy Nixon; Helga L Holst; Quarraisha Abdool Karim; Nigel C Rollins; Hoosen M Coovadia; Janet Giddy
Journal:  BMC Pediatr       Date:  2007-03-17       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.